This is a phase I open label, single-arm, dose-escalation study to evaluate the feasibility, safety, tolerability, PK/PD, and to determine RP2D of MT027 via an locoregional delivery in subjects with pleural malignant tumors, who have previously received standard of care therapy.. Subjects meeting the study entry criteria including having tumor antigen B7H3 overexpression via immunohistochemistry (IHC ) will be enrolled and assigned to cohorts sequentially to receive study treatments, assessments, as well as post-treatment safety follow-ups in the study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
adverse events (AE) and serious adverse events (SAE)
Timeframe: through study completion, an average of 1 year
Dose Limiting Toxicity (DLT)
Timeframe: 28 days
GvHD
Timeframe: through study completion, an average of 1 year
CRS
Timeframe: through study completion, an average of 1 year
Immune effector cell-associated neurotoxicity syndrome (ICANs)
Timeframe: through study completion, an average of 1 year